Inflammatory Regulation Effect of NAC on COVID-19 Treatment

• Status: Not yet recruiting
• Trial end date: 2021-08-30
• Target enrollment: 0
• Participant gender: All

Summary

Study times to evaluate the efficacy of N-Acetylcysteine therapy in the management of adult admitted patients with COVID-19.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dr. Tariq Alhawassi
• Treatments: Acetylcysteine; N-monoacetylcystine

Criteria

Inclusion Criteria:

• Adult above 18 years of age

• Admitted to the hospital With confirmed COVID-19 by RT-PCR test

• On oxygen supplement

Exclusion Criteria:

• Active use of NAC

• Known NAC allergy

• In the opinion of the treating team, progression of death is imminent and inevitable within the next 24 hour, irrespective of provision treatment

• All patients enrolled in any other investigational drug studies in COVID-19.